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botic events when added to standard antiplatelet therapy in patients with stable atherosclerotic vascular disease.
OBJECTIVES The goal of this study was to test the hypothesis that treatment with vorapaxar reduces the rate of
coronary stent thrombosis (ST) in stable patients with a history of coronary stenting.
METHODS TRA 2P-TIMI 50 (Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With
Atherosclerosis-Thrombolysis InMyocardial Infarction50)wasamultinational, randomized,double-blind,placebo-controlled
trial of vorapaxar in stable patients with prior myocardial infarction, peripheral arterial disease, or stroke. We evaluated the
rates of deﬁnite ST as adjudicated by a central events committee using Academic Research Consortium (ARC) criteria.
RESULTS A total of 26,449 patients were randomized, with 14,042 (53%) having a history of a coronary stent
implantation before randomization, and an additional 449 patients receiving a coronary stent during the trial (total
14,491). During follow-up (median 2.5 years), there were 152 deﬁnite ST events, with the majority (92%) occurring late or
very late. Vorapaxar reduced ARC deﬁnite ST (1.1% vs. 1.4%, hazard ratio [HR]: 0.71, 95% conﬁdence interval [CI]: 0.51 to
0.98; p ¼ 0.037). The reduction was consistent, regardless of time from percutaneous coronary intervention, history of
diabetes, use of drug-eluting stents, and use of dual antiplatelet therapy (DAPT) at randomization. Vorapaxar increased
GUSTO moderate/severe bleeding (HR: 1.57, 95% CI: 1.26 to 1.94; p < 0.001).
CONCLUSIONS The rate of ARC deﬁnite ST in stable patients, the majority of whom were receiving DAPT, was
approximately 1.4% at 3 years. In stable patients with coronary stenting receiving standard antiplatelet therapy,
vorapaxar administered for long-term secondary prevention signiﬁcantly reduced ARC deﬁnite ST, including very late ST.
(Trial to Assess the Effects of Vorapaxar [SCH 530348; MK-5348] in Preventing Heart Attack and Stroke in Patients
With Atherosclerosis [TRA 2P-TIMI 50] [P04737]; NCT00526474) (J Am Coll Cardiol 2014;64:2309–17) © 2014 by the
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FDA = U.S. Food and Drug
Administration
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PAD = peripheral artery
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ST = stent thrombosis
TIA = transient ischemic at
and GlaxoS
as a consul
Merck & Co
Lilly and C
received re
Morrow h
BRAHMS,
GlaxoSmith
gulex; and
Gilead, Ins
Servier. M
Listen to
You can a
Manuscript
Bonaca et al. J A C C V O L . 6 4 , N O . 2 2 , 2 0 1 4
Vorapaxar and Stent Thrombosis D E C E M B E R 9 , 2 0 1 4 : 2 3 0 9 – 1 7
2310S tents are routinely used in coronaryinterventions to reduce the risk ofcomplications such as acute dissection
and recoil, as well as late coronary resteno-
sis. Stent thrombosis (ST) is an uncommon,
but serious, complication of coronary stent-
ing, and may occur at various times after im-
plantation. ST may be classiﬁed on the basis
of timing as acute (<24 h), subacute (24 h
to 30 days), late (30 days to 1 year), and
very late (>1 year) (1–3). Late and very late
ST occur at a lower rate than acute and
subacute ST, but remain a life-threatening
complication (4,5).SEE PAGE 2327Dual antiplatelet therapy with aspirin and
an adenosine diphosphate (ADP) receptor
blocker reduces ST compared with aspirin
monotherapy. Newer generations of more
potent ADP receptor blockers (e.g., prasu-
grel, ticagrelor) further reduce this risk rela-
tive to clopidogrel within the ﬁrst year afteran acute coronary syndrome (ACS) (6,7). It is un-
known whether intensive antiplatelet therapy in pa-
tients with stable coronary artery disease and prior
coronary stenting reduces later events, particularly
very late ST. It is also not known whether antiplatelet
agents targeting novel receptors and pathways are
effective at modifying the risk of stent-related events.
The TRA 2P-TIMI 50 trial (Trial to Assess the Ef-
fects of Vorapaxar in Preventing Heart Attack and
Stroke in Patients With Atherosclerosis-Thrombolysis
In Myocardial Infarction 50) studied vorapaxar, a
novel antiplatelet agent acting through inhibition of
the platelet protease-activated receptor (PAR)-1, for
long-term secondary prevention when added to
standard antiplatelet therapy, including aspirin (98%)
and a thienopyridine (78%), in patients with stable
atherosclerosis, including prior myocardial infarction
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received April 8, 2014; revised manuscript received August 6, 20(MI), prior stroke, and peripheral arterial disease
(PAD) (8,9). We tested the hypothesis that PAR-1
inhibition with vorapaxar would reduce the risk of
ST in stable patients in whom a coronary stent was
implanted, and evaluated whether any effect
observed was modiﬁed by background antiplatelet
therapy or timing from stent implantation.
METHODS
STUDY POPULATION AND PROCEDURES. TRA
2P-TIMI 50 was a multinational, randomized, double-
blind, placebo-controlled trial among 26,449 subjects
with stable atherosclerotic vascular disease man-
ifested by prior MI, PAD, or ischemic stroke (8). The
trial design details were previously reported (8,9).
Participants in whom a coronary stent was implanted
before randomization or who received a coronary
stent during follow-up are the basis for the present,
pre-speciﬁed analysis. For patients receiving a ﬁrst
coronary stent during follow-up, observation was
started at the time of stent placement. Additional
analyses of safety and efﬁcacy using this pre-
speciﬁed population with coronary stents, but ex-
cluding patients with history of stroke or transient
ischemic attack (TIA), are presented in the Results
section, consistent with the population approved for
the use of vorapaxar by the U.S. Food and Drug
Administration (FDA) (10).
Patients with MI qualiﬁed for the trial on the basis
of a history of spontaneous MI occurring 2 weeks to 12
months before randomization (8). In order to qualify
for inclusion on the basis of PAD, patients were
required to have a history of intermittent claudication
in conjunction with an ankle-brachial index <0.85 or
previous revascularization for limb ischemia. Patients
with qualifying stroke were required to have a history
of symptomatic ischemic stroke occurring 2 weeks
to 12 months before randomization. Patients were
ineligible if they had a planned revascularization thatarini International, and Medscape; has received fees
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TABLE 1 Baseline Characteristics (Randomized Treatment Allocation)
Vorapaxar
(n ¼ 7,223)
Placebo
(n ¼ 7,268) p Value
Demographics
Age, yrs 59 (52–67) 59 (51–66) 0.31
Female 1,426 (20) 1,370 (19) 0.17
White race 6,551 (91) 6,548 (90) 0.19
Weight <60 kg 342 (5) 326 (5) 0.48
Clinical characteristics
Diabetes mellitus 1,605 (22) 1,595 (22) 0.69
Hypertension 4,582 (63) 4,650 (64) 0.49
Hyperlipidemia 6,203 (86) 6,234 (86) 0.86
Current smoker 1,469 (20) 1,553 (21) 0.13
Peripheral artery disease 985 (14) 1,007 (14) 0.70
CrCl at baseline <60 ml/min 686 (10) 633 (9) 0.11
Coronary artery bypass grafting 649 (9) 690 (10) 0.29
Prior myocardial infarction 6,967 (97) 7,001 (96) 0.71
Prior STEMI 3,890 (57) 3,812 (56) 0.11
Drug-eluting stent 3,237 (46) 3,282 (47) 0.65
Baseline medical therapy
Aspirin 7,072 (98) 7,134 (98) 0.28
Thienopyridine 6,147 (85) 6,141 (85) 0.31
Aspirin and thienopyridine therapy 6,011 (83) 6,028 (83) 0.65
Values are median (interquartile range) or n (%).
CrCl ¼ creatinine clearance; STEMI ¼ ST-segment elevation myocardial infarction.
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2311had not yet been performed, had a history of a
bleeding diathesis, a history of intracranial hemor-
rhage, or were receiving vitamin K antagonist therapy.
Details of prior coronary stenting were collected
for all patients at baseline, and information for new
coronary stents were collected during follow-up. The
institutional review board or ethics committee for
each participating institution approved the trial. All
patients gave written informed consent.
Randomization was stratiﬁed both by qualifying
disease state and by the pre-randomization assess-
ment of whether use of a thienopyridine was planned
(8). Eligible patients were randomized in a 1:1 fashion
to receive vorapaxar 2.5 mg daily or matching
placebo.
ENDPOINTS. The primary efﬁcacy and safety deﬁni-
tions, as well as the results of the TRA 2P-TIMI 50
trial were previously described (9). All potential ST
events during the trial were collected through inves-
tigator report and prospective review of all cases of
death, MI, urgent coronary revascularization, and
unstable angina for possible unreported ST. Source
documents, including hospitalization records and
angiogram reports, were collected for all potential ST
events and assembled into endpoint packets for re-
view and formal adjudication by the clinical events
committee (8).
To qualify as deﬁnite thrombosis in accordance
with the Academic Research Consortium (ARC) (1),
there needed to be an angiographic report doc-
umenting Thrombolysis In Myocardial Infarction
(TIMI) ﬂow grade 0 with occlusion originating in the
stent or in the segment 5 mm proximal or distal to the
stented region in the presence of a thrombus, or TIMI
ﬂow grade 1, 2, or 3 and the presence of thrombus
originating in the stent or in the segment 5 mm
proximal or distal to the stented region and at least 1
of the following criteria: new onset of ischemic
symptoms at rest (typical pain >20 min); new
ischemic electrocardiographic changes suggestive of
acute ischemia; typical rise and fall in cardiac bio-
markers (1,9). Any unexplained death within 30 days
of coronary stenting, or MI at any time occurring in
the territory of an implanted stent without angio-
graphic conﬁrmation, or other obvious cause quali-
ﬁed as probable ST, and any unexplained death more
than 30 days after coronary stenting qualiﬁed as
possible ST, in accordance with the ARC criteria (9).
Incidental angiographic documentation of silent stent
occlusion in the absence of clinical signs or symptoms
was not considered a conﬁrmed ST (9).
STATISTICAL METHODS. Baseline characteristics
were compared using the chi-square test forcategorical variables and the Wilcoxon rank sum test
for continuous ones. Efﬁcacy analyses were per-
formed using a Cox proportional hazards model, with
the investigational treatment allocation and planned
use of a thienopyridine as covariates. In addition,
subgroups of interest were analyzed using the Cox
model and including the subgroup, randomized
treatment, and relevant interaction terms. Cumula-
tive event rates at 3 years were calculated with the
Kaplan-Meier method. Efﬁcacy data were analyzed on
an intention-to-treat basis. Analyses were performed
using Stata version 12.1 (Stata Corp., College Station,
Texas).
RESULTS
BASELINE CHARACTERISTICS. A total of 14,491
patients had at least 1 coronary stent. Of these
patients, 14,042 (97%) had a coronary stent before
randomization, and 449 (3%) received a ﬁrst coro-
nary stent during follow-up. Just under one-half of
patients (47%) had drug-eluting stents (DES). The
median duration of follow-up was 2.5 years. The
median time from most recent coronary stent im-
plantation to randomization was 3 months. Baseline
characteristics were balanced between treatment
groups and are shown in Table 1. The majority of
patients (93%) with coronary stents qualiﬁed for the
trial with a recent MI, 22% were diabetic, 98%
FIGURE 1 Timing of Individual ST Events From Time of PCI
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Overall, 1% of events were acute, 7% were subacute, 27% were late, and 65% were very
late. Of the total, 92% of deﬁnite stent thrombosis (ST) events were late or very late.
PCI ¼ percutaneous coronary intervention.
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2312received aspirin, and 83% received dual antiplatelet
therapy (DAPT) with aspirin and a thienopyridine,
predominantly clopidogrel. Use of other background
cardiovascular therapies was frequent, including
statins (95%) and angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers (79%).
STENT THROMBOSIS. During follow-up there were
152 occurrences of ARC deﬁnite ST. The majority
(92%) of events in this stable secondary preven-
tion population occurred late or very late (>1 year)
after stent implantation (Figure 1, Online Figure 1).
Deﬁnite ST events occurring more than 1 year
from stent implantation (65%) were distributed
evenly over the follow-up period (Figure 1). The rate
of ARC deﬁnite ST in the placebo group was 1.4%
at 3 years (0.47% annualized). There were 169
patients with deﬁnite/probable ST (placebo event rate
0.50% annualized), and 310 patients with deﬁnite/
probable/possible ST (placebo event rate of 0.90%
annualized).
Compared with the 14,339 patients with coronary
stents who did not develop deﬁnite ST, subjects who
experienced a deﬁnite ST event (ARC deﬁnite) were
younger, had a greater prevalence of dyslipidemia
and current tobacco use, and more frequently had
DES (61% vs. 46%; p < 0.001) (Online Table 1). There
was no signiﬁcant regional heterogeneity in the
occurrence of deﬁnite ST (p ¼ 0.07).
EFFECT OF PAR-1 INHIBITION WITH VORAPAXAR
ON ST. Vorapaxar signiﬁcantly reduced ARC deﬁniteST compared with placebo by 29% (1.1% vs. 1.4%,
hazard ratio [HR]: 0.71, 95% conﬁdence interval [CI]:
0.51 to 0.98; p ¼ 0.037) (Table 2, Figure 2). This
reduction was directionally consistent in all sub-
groups, including prior ST-segment elevation MI,
whether or not the patient had a DES, and smoking
status (Figure 3). Patients with diabetes had a
numerically greater reduction in deﬁnite ST with
vorapaxar (0.60% vs. 1.57%, HR: 0.38, 95% CI: 0.17 to
0.85; p ¼ 0.019) compared with nondiabetic patients
(1.21% vs. 1.37%, HR: 0.81, 95% CI: 0.57 to 1.16;
p ¼ 0.25); however, there was no deﬁnite statistical
heterogeneity (p for interaction ¼ 0.092) (Figure 3).
The reduction in deﬁnite ST was consistent when
limiting the population to stented patients who
qualiﬁed for the trial with MI or PAD and had no
history of stroke or TIA (1.0% vs. 1.4%, HR: 0.70, 95%
CI: 0.50 to 0.98; p ¼ 0.039) (Table 2, Online Table 2,
Figure 3). In addition, ﬁndings were numerically
consistent, but no longer statistically signiﬁcant,
when using broader, less speciﬁc deﬁnitions of ST,
including deﬁnite/probable ST (HR: 0.74, 95% CI: 0.55
to 1.01; p ¼ 0.058) and deﬁnite/probable/possible ST
(HR: 0.84, 95% CI: 0.67 to 1.05; p ¼ 0.12) (Table 2).
TIMING OF ST. The reduction in deﬁnite ST with
vorapaxar was consistent at all previously deﬁned
times, including events occurring within the ﬁrst
month, from 30 days to 1 year, and after 1 year
(Figure 4). Very late ST was signiﬁcantly reduced
with vorapaxar (HR: 0.65, 95% CI: 0.43 to 0.97;
p ¼ 0.037).
OUTCOMES AFTER ST. Deﬁnite ST required docu-
mentation of ST, thereby excluding patients who died
before angiography; however, 11% (16 of 152) died
after a deﬁnite ST event, with the majority (11 of 16)
dying within 4 days. Mortality after deﬁnite/probable
ST was 14% (23 of 169), with the majority (13 of 23)
occurring at the time of the event.
INFLUENCE OF BACKGROUND ANTIPLATELET
THERAPY. The majority of patients were on back-
ground aspirin (98%) and, when stratiﬁed by aspirin
dose (low dose #150 mg, high dose >150 mg), there
was no heterogeneity in the reduction in deﬁnite ST
with vorapaxar (high dose HR: 0.62, 95% CI: 0.34 to
1.13; low dose HR: 0.78, 95% CI: 0.53 to 1.15; p for
interaction ¼ 0.52) compared with placebo.
The majority (83%) of patients were on DAPT with
aspirin and a thienopyridine (w98% clopidogrel) at
baseline. The reduction in deﬁnite ST was similar in
those planned for thienopyridine therapy (HR: 0.72,
95% CI: 0.51 to 1.02) and those not planned for thie-
nopyridine therapy (HR: 0.67, 95% CI: 0.29 to 1.54)
(p for interaction ¼ 0.88) (Figure 5).
TABLE 2 Efﬁcacy and Safety Endpoints
Endpoint Vorapaxar Placebo
Hazard Ratio
(95% CI) p Value
All patients with coronary stents 7,223 7,268
Stent thrombosis
Deﬁnite 63 (1.1) 89 (1.4) 0.71 (0.51–0.98) 0.037
Deﬁnite or probable 72 (1.2) 97 (1.5) 0.74 (0.55–1.01) 0.058
Deﬁnite, probable or possible 141 (2.2) 169 (2.7) 0.84 (0.67–1.05) 0.12
Major cardiovascular events
CV death, MI, stroke 565 (9.1) 680 (10.7) 0.83 (0.74–0.93) 0.001
CV death 120 (1.9) 134 (2.2) 0.90 (0.71–1.16) 0.43
MI 423 (6.9) 515 (8.1) 0.82 (0.72–0.94) 0.003
Ischemic stroke 62 (1.1) 92 (1.5) 0.68 (0.49–0.94) 0.019
Bleeding
ICH 34 (0.6) 23 (0.4) 1.51 (0.89–2.56) 0.13
Fatal bleed 12 (0.2) 8 (0.1) 1.53 (0.63–3.75) 0.35
GUSTO moderate 146 (2.6) 83 (1.4) 1.79 (1.37–2.35) <0.001
GUSTO severe 70 (1.2) 58 (1.0) 1.23 (0.87–1.74) 0.25
GUSTO moderate or severe 209 (3.6) 136 (2.3) 1.57 (1.26–1.94) <0.001
Vorapaxar Placebo
Hazard Ratio
(95% CI) p Value NNT/NNH
Patients with coronary stents
and no stroke or TIA
(FDA-approval
population)
6,813 6,846
Stent thrombosis
Deﬁnite 59 (1.1) 84 (1.4) 0.70 (0.50–0.98) 0.039 277
Deﬁnite or probable 66 (1.2) 91 (1.5) 0.73 (0.53–1.00) 0.049
Deﬁnite, probable or
possible
129 (2.2) 158 (2.7) 0.82 (0.65–1.04) 0.10
Major cardiovascular events
CV death, MI, stroke 479 (8.1) 604 (9.9) 0.79 (0.70–0.89) <0.001 56
CV death 105 (1.8) 117 (2.1) 0.91 (0.70–1.18) 0.47
MI 370 (6.3) 459 (7.6) 0.81 (0.70–0.93) 0.002
Ischemic stroke 39 (0.7) 76 (1.3) 0.52 (0.35–0.76) <0.001
Bleeding
ICH 27 (0.5) 22 (0.4) 1.25 (0.71–2.19) 0.44 1,334
Fatal bleed 10 (0.2) 6 (0.1) 1.69 (0.62–4.66) 0.31 1,691
GUSTO moderate 130 (2.4) 75 (1.3) 1.76 (1.33–2.34) <0.001
GUSTO severe 60 (1.1) 53 (0.9) 1.15 (0.79–1.66) 0.46
GUSTO moderate or severe 185 (3.4) 125 (2.2) 1.50 (1.20–1.89) <0.001 112
Values are n or n (%) except as indicated.
CI ¼ conﬁdence interval; CV ¼ cardiovascular; FDA ¼ U.S. Food and Drug Administration; GUSTO ¼ Global
Utilization Of Streptokinase and tPA for Occluded arteries; ICH ¼ intracranial hemorrhage; MI ¼ myocardial
infarction; NNH ¼ number needed to harm; NNT ¼ number needed to treat; TIA ¼ transient ischemic attack.
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2313To determine whether the reduction in deﬁnite ST
with vorapaxar was consistent in patients treated
with long-term thienopyridine therapy, a sensitivity
analysis was performed, evaluating the effect of
vorapaxar in the subgroup of patients treated with
thienopyridine, both at baseline and at 18 months
or the end of follow-up (long-term thienopyridine:
n ¼ 6,779, 59% of those on DAPT at baseline).
The reduction in deﬁnite ST with vorapaxar was
consistent in patients on long-term thienopyridine
therapy (HR: 0.72, 95% CI: 0.51 to 1.04), without
heterogeneity from the effect of vorapaxar in pa-
tients who were on a thienopyridine at randomiza-
tion, but stopped before 18 months (short-term
thienopyridine 41%, HR: 0.87, 95% CI: 0.33 to 2.25;
p for interaction ¼ 0.73).
EFFICACY AND BLEEDING IN PATIENTS WITH
CORONARY STENTS. Consistent with the primary
ﬁndings in the overall trial, in the population with
coronary stents, vorapaxar reduced the primary
endpoint of cardiovascular death, MI, or stroke (HR:
0.83, 95% CI: 0.74 to 0.93; p ¼ 0.001) (Table 2) with
beneﬁt driven primarily by reductions in MI (HR:
0.82, 95% CI: 0.72 to 0.94; p ¼ 0.003) (Table 2) and
ischemic stroke (HR: 0.68, 95% CI: 0.49 to 0.94;
p ¼ 0.02) (Table 2). GUSTO (Global Utilization Of
Streptokinase and Tpa for Occluded arteries) mod-
erate or severe bleeding was increased (HR: 1.57, 95%
CI: 1.26 to 1.94) (Table 2). In this population with
coronary stents, severe bleeding events, including
intracranial hemorrhage (placebo rate 0.4% at 3
years, or 0.13% per year) and fatal bleeding (0.1% at 3
years or 0.03% per year) (Table 2), were infrequent.
In this cohort, rates of intracranial hemorrhage and
fatal bleeding were not statistically increased with
vorapaxar (Table 2). When examined among patients
in the FDA-approval population (MI or PAD and no
history of stroke or TIA) who had coronary stents,
ﬁndings with vorapaxar were similar, with a reduc-
tion in deﬁnite ST (HR: 0.70, 95% CI: 0.50 to 0.98;
p ¼ 0.039, number needed to treat [NNT] ¼ 277) and
cardiovascular death/MI/stroke (HR: 0.79, 95% CI:
0.70 to 0.89; p < 0.001, NNT ¼ 56), but an increase in
GUSTO moderate or severe bleeding (HR: 1.50, 95%
CI: 1.20 to 1.89; p < 0.001, number needed to harm
[NNH] ¼ 112) (Table 2).
DISCUSSION
In stable patients with established atherosclerosis
and a history of coronary stenting, adding vorapaxar
to standard background antiplatelet therapy for long-
term secondary prevention of atherothrombotic
events reduced deﬁnite ST (Central Illustration). Thisreduction was consistent, regardless of the dose
of aspirin used or the use of a thienopyridine.
Notably, vorapaxar reduced the incidence of very
late ST (occurring more than a year after implanta-
tion) with consistent beneﬁt at all time points from
stent implantation. Together, these ﬁndings identify
PAR-1 as a therapeutic target for reducing the risk
of deﬁnite ST in long-term secondary prevention
(Central Illustration). As anticipated, this potent
antiplatelet drug increased bleeding. However, there
was no increase in fatal or intracranial bleeding
FIGURE 2 Deﬁnite ST by Randomized Treatment
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This ﬁgure shows ARC deﬁnite stent thrombosis (ST) events
over 1,080 days (3 years) from randomization stratiﬁed by
treatment allocation (vorapaxar in salmon, placebo in blue).
ARC ¼ Academic Research Consortium; HR ¼ hazard ratio.
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2314with vorapaxar in this population with coronary
stents.
ANTIPLATELET THERAPY AND VERY LATE ST. The
incidence of very late ST is not well established, with
few robustly sized studies of patients with stableFIGURE 3 Hazard of Deﬁnite ST by Subgroup
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This ﬁgure shows the consistent reduction of ARC deﬁnite stent thrombos
including presence of diabetes mellitus, smoking stats, timing of most r
of a drug-eluting stent (DES). *Time from index myocardial infarction to
outside of North America. Hx ¼ history; MI ¼myocardial infarction; NA ¼
TIA ¼ transient ischemic attack; other abbreviations as in Figure 2.coronary artery disease and coronary stents receiving
modern therapy. In a recent publication, the annual-
ized rate of deﬁnite ST after ACS was 1.93% in pa-
tients with ACS within a year (7). A recently published
meta-analysis, including patients receiving percuta-
neous coronary intervention for any indication (sta-
ble coronary artery disease and ACS), reported a
composite 1.5% incidence of deﬁnite ST at 22 months
(0.81% annualized) (11).
In this population of stable patients with prior MI,
98% on aspirin and 83% on DAPT, we observed an
annual rate of deﬁnite ST of 0.47%. Of note, although
the majority of patients had a history of MI in the last
year, ST events continued to occur at a linear rate
even a year after stent implantation, without any sign
of decreasing frequency with time. Because of this
constant risk, the stable nature of our cohort, and the
3 years of follow-up (placebo group in Figure 2), the
majority of events (65%) accrued more than a year
after stent implantation.
Although the absolute rate of deﬁnite ST is low rela-
tive to de novo MI, as we previously reported in
the cohort who qualiﬁed with MI (2.7% per year), it
is similar to that of ischemic stroke in the same popula-
tion (1.5% at 3 years, 0.47% per year) (12). Similar topaxar Reduced with Placebo1.0
HR (95% CI)
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is with vorapaxar compared to placebo when examined by subgroups,
ecent myocardial infarction (MI), aspirin (ASA) dose, and presence
randomization. **Randomized in North America versus randomized
North America; STEMI ¼ ST-segment elevation myocardial infarction;
FIGURE 4 Consistent Reduction in ARC Deﬁnite ST With Vorapaxar by
Timing of the Event
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Stent thrombosis events are divided into acute/subacute (occurred in 12, or 0.08%, at
30 days, orange), late (occurred in 41, or 0.28%, from 30 days to 1 year, yellow), and very
late (occurred in 99, or 0.68%, over an average of 2.5 years, green). CI ¼ conﬁdence
interval; other abbreviations as in Figure 2.
FIGURE 5 ARC Deﬁnite Thrombosis Over 1,080 Days (3 Years) With Vorapaxar
Versus Placebo
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This ﬁgure shows the ARC deﬁnite thrombosis over 1,080 days (3 years) with vorapaxar
(salmon) versus placebo (blue) stratiﬁed by background thienopyridine use. Abbreviations
as in Figure 2.
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2315ischemic stroke, ST remains a feared ischemic outcome
because of high rates of associated mortality. In a recent
analysis from the PLATO (Study of Platelet Inhibition
and Patient Outcomes) trial, ST was associated with
increased rates of all-cause mortality, with a similar
pattern observed in the current cohort (7). This concern
has been the impetus for a series of trials investigating
whether prolonged DAPT with aspirin and a thieno-
pyridine can modify the risk of late ischemic events (13).
Completed trials of prolonged DAPT beyond a year
from stenting have not shown reduction of ischemic
events or ST; however, these trials may have been
underpowered for rare events (14,15). PAR-1 is
expressed on a variety of cell types, including
vascular smooth muscle and endothelium, and in-
hibition of PAR-1 in animals was shown to have
antimitogenic effects in balloon-injured vessels.
Vorapaxar was shown to reduce peripheral revascu-
larization in a manner that suggests mechanisms
beyond that of platelet inhibition alone (16). Whether
the beneﬁt of vorapaxar in reduction of deﬁnite ST is
solely mediated by PAR-1 antagonism on platelets is
uncertain and warrants further study.
Although this analysis was focused on the question
of whether PAR-1 inhibition reduces coronary ST in
stable patients with a history of stenting, data are
presented regarding the broad efﬁcacy and safety of
vorapaxar in patients with coronary stents and no
history or stroke or TIA (FDA-approval population).
On the basis of the overall reduction in major adverse
cardiovascular events (cardiovascular death, MI, or
stroke), the NNT is 56 in the stented population.
Because ST is infrequent in stable patients, the NNT
for vorapaxar for this endpoint is 227. GUSTO mod-
erate or severe bleeding was increased with an NNH
of 112. There were numeric but not statistically sig-
niﬁcant increases in GUSTO severe bleeding (NNH ¼
939), intracranial hemorrhage (NNH ¼ 1,334), and
fatal bleeding (NNH ¼ 1,691). It is not possible to
comment on the magnitude of beneﬁt of other
antithrombotics (e.g., prasugrel or ticagrelor) in this
population, as they have not yet been studied in this
stable setting. Ongoing trials will provide such data in
the future.
STUDY LIMITATIONS. First, the adjudication of ST in
this study was performed using detailed medical re-
cords, including angiographic reports, rather than
central review of the angiograms. Although use of
central “core lab” angiographic review increases
detection of ST, the process used in this study is
consistent with that used in several recent analyses of
ST (6,7,17). The impact would only be expected to
diminish our power to detect a difference betweentherapies, and any loss of speciﬁcity would be ex-
pected to bias our analyses toward the null result.
Secondly, because of this trial’s timing, contemporary
antiplatelet therapy after stenting was predominantly
with clopidogrel. Although we have shown that PAR-1
antagonism with vorapaxar adds to ADP receptor
CENTRAL ILLUSTRATION The Role of PAR-1 in the Pathogenesis of Stent Thrombosis
Bonaca, M.P. et al. J Am Coll Cardiol. 2014; 64(22):2309–17.
Thrombin activation of protease-activated receptor (PAR-1) and the pathogenesis of stent thrombosis. Vorapaxar is a PAR-1 antagonist, which blocks thrombin mediated
platelet activation and reduces stent thrombosis.
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2316pathway inhibition, we do not have data to address
this question in the setting of more potent inhibition
with prasugrel or ticagrelor. In addition, although
speciﬁc DES types are not available, the types repre-
sented may include those used during and prior to
2007, when the trial completed recruitment. There-
fore, ﬁndings, particularly regarding absolute rates of
ST, should not be extrapolated to later-generation
stent types. Thirdly, despite this study’s large sam-
ple size, given the low overall incidence of late and
very late ST, our statistical power to identify hetero-
geneity in some subgroup analyses is low. Fourthly,
the effect of vorapaxar on broader, less speciﬁc ST
endpoints was numerically consistent with that
observed for deﬁnite ST, but no longer statistically
signiﬁcant. Deﬁnite ST is the most speciﬁc of the ARC
endpoints, and is therefore most likely to represent
the true effect of therapy on ST. Broader deﬁnitions,
such as probable ST and possible ST, include events
such as unexplained death, which may or may not berelated to ST, and thus, although they increase the
total number of events, they decrease the speciﬁcity
of the endpoint for true ST. Lastly, although the
ﬁndings may appear to contrast with those from the
TRACER (Thrombin Receptor Antagonist for Clinical
Event Reduction in Acute Coronary Syndrome) trial,
in which ST was not signiﬁcantly reduced, updated
analyses from this trial using angiographic adjudica-
tion have shown a consistent reduction with vor-
apaxar, further supporting the ﬁndings of this
analysis (18).
Any clinical use of vorapaxar would have to weigh
the observed reduction in ST and other thrombotic
events (9) against the risk of bleeding. Nevertheless,
our ﬁndings provide important evidence for PAR-1
antagonism as a viable target for reducing late and
very late ST, and indicate that a reduction in deﬁnite
ST is an antithrombotic beneﬁt of vorapaxar to be
considered in weighing its potential beneﬁts versus
risks for the individual patient.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In stable
patients with coronary stents, the PAR-1 receptor antagonist
vorapaxar reduced the risk of stent thrombosis by appro-
ximately 30% compared with placebo when added to
aspirin or dual anti-platelet therapy with aspirin and a
thienopyridine.
TRANSLATIONAL OUTLOOK: Further studies are needed
to more accurately identify patients most likely to beneﬁt
from long-term therapy with vorapaxar and determine
whether efﬁcacy would be diminished or safety enhanced
if aspirin were withdrawn from the combination regimen.
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2317CONCLUSIONS
In stable patients with established atherosclerosis
and a history of coronary stenting, long-term therapy
with vorapaxar reduced the risk of deﬁnite ST.
The beneﬁt was consistent over time, including a
reduction in very late events, occurring more than a
year after stent implantation, and was not modiﬁed
by background use of DAPT with aspirin and a
thienopyridine.
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